Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Sensorion appoints Aniz Girach as Independent Board Member
Sensorion appoints Aniz Girach as Independent Board Member


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease


ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that the

Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)
Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)


Regulatory News:



Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has entered into a €15 million

Lysogene Awarded Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program
Lysogene Awarded Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that the Medicines and

Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...


 



ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60

ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share


Regulatory News:



ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for

Valbiotis meldet die Einreichung von drei klinischen Protokollen für den zur Blutdrucksenkung indizierten Wirkstoff TOTUM•854 bei den zuständigen Behörden und stellt seinen Plan für eine umfassende klinische Entwicklung vor
Valbiotis meldet die Einreichung von drei klinischen Protokollen für den zur Blutdrucksenkung indizierten Wirkstoff TOTUM•854 bei den zuständigen Behörden und stellt seinen Plan für eine umfassende klinische Entwicklung vor


Pflichtmeldung:



Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert) (Paris:AVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation

EQS-Adhoc: Veränderung im Verwaltungsrat von Newron
EQS-Adhoc: Veränderung im Verwaltungsrat von Newron
EQS-Adhoc: Veränderung im Verwaltungsrat von Newron
EQS-Adhoc: Change in Newron Board of Directors
EQS-Adhoc: Change in Newron Board of Directors
EQS-Adhoc: Change in Newron Board of Directors
DGAP-Adhoc: Veränderung im Verwaltungsrat von Newron
DGAP-Adhoc: Veränderung im Verwaltungsrat von Newron
DGAP-Adhoc: Veränderung im Verwaltungsrat von Newron
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan


Regulatory News:



Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:AVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Nova Mentis Life Science Completes Acquisition of Pilz Bioscience
Nova Mentis Life Science Completes Acquisition of Pilz Bioscience

Vancouver, British Columbia – December 1, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that, further to its

Nova Mentis Life Science schließt Übernahme von Pilz Bioscience ab
Nova Mentis Life Science schließt Übernahme von Pilz Bioscience ab

Vancouver, British Columbia – 1. Dezember 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FWB: HN3Q) (OTCPK: LIBFF) („NOVA“ oder das „Unternehmen“) freut sich bekannt zu geben, dass im

Sirona Biochem veröffentlicht Schreiben des CEO an die Aktionäre
Sirona Biochem veröffentlicht Schreiben des CEO an die Aktionäre

Vancouver, CanadaNovember 30, 2020Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to provide an update from the Company’s CEO, Dr. Howard Verrico.

 

Sirona Biochem Releases CEO Letter to Shareholders
Sirona Biochem Releases CEO Letter to Shareholders

Vancouver, Kanada – 30. November 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (US-OTC: SRBCF) („Sirona“) freut sich, ein Update von Dr. Howard J. Verrico, dem CEO des Unternehmens, zu

True Leaf informiert über aktuellen Stand des Handelsverbots für das Management
True Leaf informiert über aktuellen Stand des Handelsverbots für das Management

 

Vernon (BC), 23. November 2020. True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FWB: TLA) („True Leaf“ oder das „Unternehmen“) stellt diesen zweiwöchentlichen Statusberichts im Einklang

True Leaf Provides Management Cease Trade Order Update
True Leaf Provides Management Cease Trade Order Update

Vernon, BC - November 23, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf” or the “Company”) is providing a biweekly default status report in accordance with

Relay Medical & Fio Announce Pilot for COVID-19 Rapid Testing with Lonestar Life Sciences at Rural Hospitals in Texas
Relay Medical & Fio Announce Pilot for COVID-19 Rapid Testing with Lonestar Life Sciences at Rural Hospitals in Texas

November 20, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”), together Fionet Rapid Response Group (“FRR”) are

Relay Medical & Fio melden Pilotprojekt für COVID-19-Schnelltests mit Lonestar Life Sciences in ländlichen Krankenhäusern in Texas
Relay Medical & Fio melden Pilotprojekt für COVID-19-Schnelltests mit Lonestar Life Sciences in ländlichen Krankenhäusern in Texas

20. November 2020 - Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, gemeinsam mit der Fionet Rapid

Relay Medical & Fio to Bring Fionet Mobile COVID-19 Testing & Tracking Platform to Private School Campus and Hockey Rink in the Greater Toronto Area
Relay Medical & Fio to Bring Fionet Mobile COVID-19 Testing & Tracking Platform to Private School Campus and Hockey Rink in the Greater Toronto Area

November 18, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”), together Fionet Rapid Response Group (“FRR”) report

Relay Medical & Fio versorgen privaten Schulcampus und Hockeyplätze im Großraum Toronto mit mobiler COVID-19-Test- & Trackingplattform Fionet
Relay Medical & Fio versorgen privaten Schulcampus und Hockeyplätze im Großraum Toronto mit mobiler COVID-19-Test- & Trackingplattform Fionet

18. November 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“), die zusammen als Fionet Rapid Response Group („F

Der Gorenje OptiBake Advanced BSA 6747 A04BG: Hochwertiger Einbau-Backofen jetzt 28% günstiger – ein Must-Have für deine Küche!: https://m.media-amazon.com/images/I/71DCqMtyMCL._AC_SL1500_.jpg
Der Gorenje OptiBake Advanced BSA 6747 A04BG: Hochwertiger Einbau-Backofen jetzt 28% günstiger – ein Must-Have für deine Küche!
Der Gorenje OptiBake Advanced BSA 6747 A04BG: Hochwertiger Einbau-Backofen jetzt 28% günstiger – ein Must-Have für deine Küche! Jetzt ansehen Hast du auf der Suche nach einem neuen Backofen die